Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/40999
Title: Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry
Authors: Seil Oh
Shinya Goto
Gabriele Accetta
Pantep Angchaisuksiri
A. John Camm
Frank Cools
Sylvia Haas
Gloria Kayani
Yukihiro Koretsune
Toon Wei Lim
Frank Misselwitz
Martin van Eickels
Ajay K. Kakkar
Seoul National University Hospital
Tokai University
Thrombosis Research Institute
Mahidol University
St George's University of London
Algemeen Ziekenhuis Klina
Technical University of Munich
Osaka National Hospital
National University Hospital, Singapore
Bayer Pharma AG
UCL
Keywords: Medicine
Issue Date: 15-Nov-2016
Citation: International Journal of Cardiology. Vol.223, (2016), 543-547
Abstract: © 2016 Elsevier Ireland Ltd Objective To compare the distribution of international normalized ratios (INRs) in patients receiving vitamin K antagonist (VKA) for newly diagnosed atrial fibrillation in Eastern and Southeastern Asia and in other regions of the world (ORW) represented in the ongoing, global observational study GARFIELD-AF. Methods and results 3621 and 13,541 patients were recruited prospectively in 2010–2013 from Asia and ORW, respectively. At baseline, excluding patients with unknown antithrombotic treatment, 1356 (37.8%) in Asia and 7081 (53.3%) in ORW received VKA (± antiplatelets). INR readings during 1-year follow-up were analyzed for VKA-treated patients with ≥ 3 measurements (878 [64.7%] patients in Asia, 4452 [62.9%] in ORW). VKA-treated patients in Asia were younger than those in ORW (mean 67.1 vs 71.3 years), with a lower CHA2DS2-VASc score (3.0 vs 3.5), but a similar HAS-BLED score (1.3 vs 1.4). Mean INR was lower in Asia than in ORW (2.0 vs 2.4). The proportion of time in the therapeutic range, defined using the multinational target of 2.0–3.0, was substantially lower in Asia (31.1% vs 54.1%). In Asia and ORW, 59.3% and 28.2% of INRs were < 2, and 9.6% and 17.7% were > 3, respectively. The same trend was found in different age groups (< 65, 65–74, ≥ 75 years). Conclusion GARFIELD-AF data demonstrate a difference in the distribution of INRs in patients from Asia versus other regions under current real-world practice. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84982299834&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/40999
ISSN: 18741754
01675273
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.